Mark D’Souza has been appointed president and chief executive officer of Labopharm and a member of the board of directors. Mr. D’Souza previously served as the company’s chief financial officer. “We are delighted to have Mark’s knowledge and experience to lead the corporation forward,” said Santo J. Costa, Labopharm’s chairman.
Mr. D’Souza replaces James Howard-Tripp, who will step down from his role. “We are very grateful to Jim for his efforts on behalf of the Corporation over the last 11 years,” said Mr. Costa.
Labopharm also announced that the board of directors, together with the company’s management, has undertaken a complete review of the business, including consideration of all available strategic options.